financetom
Business
financetom
/
Business
/
Trane Technologies Beats Q2 Expectations, Raises 2024 Guidance Amid Solid Bookings
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Trane Technologies Beats Q2 Expectations, Raises 2024 Guidance Amid Solid Bookings
Jul 31, 2024 9:58 AM

Trane Technologies plc ( TT ) shares are trading higher after the company reported better-than-expected second-quarter financial results and raised its FY24 guidance.

Revenues grew 13% Y/Y to $5.31 billion, surpassing the consensus of $5.13 billion. Bookings increased 19% Y/Y to $5.34 billion in the quarter.

Enterprise reported a 13% Y/Y increase in both revenues and organic revenues. Acquisitions contributed about 1 percentage point, which was offset by a 1 percentage point negative foreign exchange impact.

The backlog totaled $7.5 billion, including about $2.8 billion in Commercial HVAC projects for 2025 and beyond, with $1 billion added in the second quarter.

Adjusted EBITDA rose 21% Y/Y to $1.119 billion, with margin expansion of 140 bps Y/Y to 21.1%. Adjusted EPS of $3.30 surpassed the street view of $3.08.

For the six months that ended in June, cash flow from continuing operating activities was $959 million, and free cash flow was $810 million. As of June 30, cash and equivalents stood at $1.33 billion.

Year-to-date through July, the company deployed or committed around $1.2 billion in capital, including $379 million for dividends and $731 million for share repurchases.

Trane Technologies ( TT ) plans to maintain a competitive and growing dividend while deploying 100% of excess cash to shareholders over time.

Outlook: Trane Technologies ( TT ) raised FY24 organic revenue growth outlook to 10% (prior view 8% to 9%) and adjusted the EPS outlook to $10.80 (vs. consensus of $10.53) from $10.40 – $10.50.

Dave Regnery, chair and CEO said, “Given our strong first half performance and positive outlook, we are raising our full-year revenue and adjusted EPS guidance well above the high end of our prior range. With our purpose-driven strategy, proven business operating system and uplifting culture, we are well positioned to continue delivering leading growth among industrials and differentiated shareholder returns over the long term.”

Investors can gain exposure to the stock via Invesco Building & Construction ETF ( PKB ) and AdvisorShares Gerber Kawasaki ETF ( GK ) .

Price Action: TT shares are up 1.80% at $334.76 at the last check Wednesday.

Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
NKGen Biotech Cell Therapy Gets Clearance to Start Phase 2 Clinical Trial in Alzheimer's Disease; Shares Rise
NKGen Biotech Cell Therapy Gets Clearance to Start Phase 2 Clinical Trial in Alzheimer's Disease; Shares Rise
May 20, 2024
10:53 AM EDT, 05/20/2024 (MT Newswires) -- NKGen Biotech ( NKGN ) said Monday its safety review committee has cleared the company's expanded SNK01 cell therapy to progress into phase 2 clinical development in Alzheimer's disease. The phase 2trial will evaluate efficacy and further safety of SNK01 in a larger group of 30 patients with moderate Alzheimer's disease, the company...
--SL Green Realty Maintains Monthly Dividend at $0.25 Per Share, Payable June 17 to Shareholders of Record May 31
--SL Green Realty Maintains Monthly Dividend at $0.25 Per Share, Payable June 17 to Shareholders of Record May 31
May 20, 2024
10:46 AM EDT, 05/20/2024 (MT Newswires) -- Price: 53.03, Change: +0.04, Percent Change: +0.08 ...
Hannon Armstrong Gets Upgrade From Fitch
Hannon Armstrong Gets Upgrade From Fitch
May 20, 2024
10:52 AM EDT, 05/20/2024 (MT Newswires) -- Fitch Ratings on Monday upgraded the long-term issuer default ratings of Hannon Armstrong Sustainable Infrastructure Capital ( HASI ) and its indirect subsidiaries to BBB- from BB+, citing the company's enhanced business profile and funding flexibility. The rating outlook is stable amid expectation that the company will continue to expand and diversify while...
ANI Pharmaceuticals Launches Kionex Suspension
ANI Pharmaceuticals Launches Kionex Suspension
May 20, 2024
10:52 AM EDT, 05/20/2024 (MT Newswires) -- ANI Pharmaceuticals ( ANIP ) said Monday it has launched its Kionex Suspension for oral or rectal use. Kionex Suspension is therapeutically equivalent to the reference listed drug SPS Suspension for oral or rectal use, the company said. The medication is used to treat a high level of potassium in blood. Price: 61.64,...
Copyright 2023-2026 - www.financetom.com All Rights Reserved